睿知中国医院研究地图
候选清单

即将招募淋巴瘤I/II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07758491,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically and/or cytologically confirmed peripheral T-cell lymphoma or cutaneous T-cell lymphoma;

    入选标准第 3 条

  3. Have received radiotherapy within 4 weeks prior to the first dose;

    排除标准第 2 条

    Have received other anti-tumor drug therapy within 3 weeks or within 5 half-lives of the anti-tumor drug prior to the first dose;

    排除标准第 3 条

    Have previously received any therapy targeting the TRBC1 antigen or any antibody-drug conjugate with MMAE payload;

    排除标准第 5 条

    Have received autologous stem cell transplantation within 3 months prior to the first dose;

    排除标准第 6 条

    Have received high-dose systemic vitamin A therapy (daily dose >15,000 IU [i.e., 5,000 mcg]) within 3 weeks prior to the first dose of study drug;

    排除标准第 9 条

    Have received oral retinoid drugs for any indication within 3 weeks prior to the first dose;

    排除标准第 11 条

    Have adverse reactions from prior treatments that have not recovered to CTCAE v5.0 Grade ≤1 (excluding alopecia and anemia) prior to the first dose;

    排除标准第 12 条

  4. ECOG performance status of 0 or 1;

    入选标准第 6 条

  5. Have a history of other malignancies within 5 years prior to the first dose;

    排除标准第 8 条

  6. Are pregnant or breastfeeding;

    排除标准第 21 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07758491,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntarily sign the informed consent form, understand the study, are willing to comply with and have the ability to complete all trial procedures;
  2. Age 18-75 years (inclusive), any gender;
  3. Histologically and/or cytologically confirmed peripheral T-cell lymphoma or cutaneous T-cell lymphoma;
  4. Relapsed or refractory lymphoma after at least one prior line of therapy;
  5. Able to provide tumor tissue specimens;
  6. ECOG performance status of 0 or 1;
  7. Expected survival ≥3 months;
  8. Have at least one measurable tumor lesion;
  9. Adequate cardiac, bone marrow, liver, renal function;

排除标准:Exclusion Criteria:

  1. Have received a live vaccine within 3 months prior to the first dose;
  2. Have received radiotherapy within 4 weeks prior to the first dose;
  3. Have received other anti-tumor drug therapy within 3 weeks or within 5 half-lives of the anti-tumor drug prior to the first dose;
  4. Have undergone major surgery within 4 weeks prior to the first dose;
  5. Have previously received any therapy targeting the TRBC1 antigen or any antibody-drug conjugate with MMAE payload;
  6. Have received autologous stem cell transplantation within 3 months prior to the first dose;
  7. Have previously received allogeneic stem cell transplantation;
  8. Have a history of other malignancies within 5 years prior to the first dose;
  9. Have received high-dose systemic vitamin A therapy (daily dose >15,000 IU [i.e., 5,000 mcg]) within 3 weeks prior to the first dose of study drug;
  10. Have any condition requiring systemic treatment with corticosteroids (>20 mg/day prednisone or equivalent) or other immunosuppressive agents within 14 days prior to the first dose;
  11. Have received oral retinoid drugs for any indication within 3 weeks prior to the first dose;
  12. Have adverse reactions from prior treatments that have not recovered to CTCAE v5.0 Grade ≤1 (excluding alopecia and anemia) prior to the first dose;
  13. Presence or history of central nervous system lymphoma, leptomeningeal disease, or spinal cord compression;
  14. Have a history of severe allergic reactions or are allergic to the investigational drug;
  15. Have experienced a clinically significant cardiac disease within 6 months before the first dose;
  16. Have uncontrolled systemic diseases assessed by the investigator, including diabetes, hypertension, pulmonary fibrosis, interstitial lung disease, etc.;
  17. Known history of Hepatitis C or chronic active Hepatitis B;
  18. Clinically uncontrolled diseases such as diabetes mellitus, thyroid disease, or other severe systemic diseases requiring systemic treatment;
  19. Active or progressive infection requiring systemic therapy within 2 weeks prior to the first dose;
  20. Known or suspected active autoimmune disease requiring systemic therapy within 2 years prior to the first dose;
  21. Are pregnant or breastfeeding;

引自 ClinicalTrials.gov, NCT07758491, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07758491,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07758491